S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
S&P 500   4,592.03 (+1.18%)
DOW   35,254.94 (+1.95%)
QQQ   384.40 (+0.33%)
AAPL   166.15 (+2.66%)
MSFT   323.00 (+0.00%)
FB   315.07 (+2.68%)
GOOGL   2,844.97 (+0.17%)
AMZN   3,436.15 (+1.37%)
TSLA   989.00 (-2.56%)
NVDA   293.28 (-4.45%)
BABA   120.52 (+7.65%)
NIO   32.10 (-0.16%)
CGC   9.93 (-0.60%)
AMD   135.96 (-5.59%)
GE   96.51 (+4.03%)
MU   82.09 (+0.58%)
T   23.48 (+0.09%)
F   19.26 (+0.63%)
DIS   149.97 (+2.56%)
PFE   52.02 (-4.15%)
AMC   28.61 (-1.38%)
ACB   5.89 (+1.20%)
BA   205.53 (+3.55%)
NASDAQ:CRXT

Clarus Therapeutics Earnings Date, Estimates, & History

$4.21
-0.26 (-5.82%)
(As of 12/6/2021 12:05 PM ET)
Add
Compare
Today's Range
$4.14
$4.41
50-Day Range
$3.65
$5.79
52-Week Range
$3.43
$31.24
Volume
8,869 shs
Average Volume
979,544 shs
Market Capitalization
$91.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Earnings Summary

Upcoming
Earnings Date
Feb. 17
Estimated

Actual EPS
(Nov. 18)
-$0.26
Beat By $0.55

Consensus EPS
(Nov. 18)
-$0.81


Clarus Therapeutics (NASDAQ:CRXT) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20212($1.08)($0.54)($0.81)
Q4 20212($1.10)($0.54)($0.82)
20214($2.18)($1.08)($1.63)
Q1 20221($1.13)($1.13)($1.13)
Q2 20221($0.87)($0.87)($0.87)
Q3 20221($0.80)($0.80)($0.80)
Q4 20221($0.69)($0.69)($0.69)
FY 20224($3.49)($3.49)($3.49)

CRXT Earnings Information

Clarus Therapeutics last issued its earnings data on November 18th, 2021. The reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.81) by $0.55. Clarus Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Clarus Therapeutics are expected to grow in the coming year, from ($10.84) to ($2.59) per share. Clarus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 17th, 2022 based off prior year's report dates.

Clarus Therapeutics (NASDAQ:CRXT) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
2/17/2022
(Estimated)
        
11/18/20219/30/2021($0.81)($0.26)+$0.55($0.80)  
(Earnings results data provided by Zacks Investment Research)












Clarus Therapeutics (NASDAQ:CRXT) Earnings Frequently Asked Questions

When is Clarus Therapeutics's earnings date?

Clarus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 17th, 2022 based off last year's report dates. Learn more on CRXT's earnings history

Did Clarus Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Clarus Therapeutics (NASDAQ:CRXT) reported ($0.26) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.81) by $0.55. Learn more on CRXT's earnings details

How can I read Clarus Therapeutics's conference call transcript?

The conference call transcript for Clarus Therapeutics's latest earnings report can be read online. Read Transcript

How much profit does Clarus Therapeutics generate each year?

Clarus Therapeutics (NASDAQ:CRXT) has a recorded net income of -$4.72 million. CRXT has generated $0.00 earnings per share over the last four quarters.

What is Clarus Therapeutics's EPS forecast for next year?

Clarus Therapeutics's earnings are expected to grow from ($10.84) per share to ($2.59) per share in the next year.

This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.